Use of copolymer 1 and related peptides and polypeptides and T cells treated herewith for neuroprotective glaucoma therapy
US7407936B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 13, 2005 |
| Grant date | Aug 5, 2008 |
| Priority date | — |
| Expiry date | Feb 3, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.